Shopping Cart
- Remove All
Your shopping cart is currently empty
SRI-011381 hydrochloride, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer's disease.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $30 | In Stock | |
| 2 mg | $39 | In Stock | |
| 5 mg | $64 | In Stock | |
| 10 mg | $113 | In Stock | |
| 25 mg | $239 | In Stock | |
| 50 mg | $372 | In Stock | |
| 100 mg | $553 | In Stock | |
| 200 mg | $838 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $70 | In Stock |
| Description | SRI-011381 hydrochloride, a new-type agonist of the TGF-beta signaling pathway, is utilized in the treatment of Alzheimer's disease. |
| In vitro | SRI-11381 is neuroprotective. SRI-011381 promote fibrillar Aβ clearance by macrophages, as demonstrated by the dose-dependent decreases of Aβ in the conditioned medium derived from compound-treated macrophages. |
| In vivo | SRI-011381 protects mice against kainic acid-induced excitotoxicity and neurodegeneration. SRI-011381 (30 mg/kg, dissolved in DMSO) is injected (i.p.) into the SBE-luc mice. SRI-011381 is rapidly absorbed after oral administration to FBV mice with an oral bioavailability of approximately 50%. SRI-011381 by oral gavage of 10, 30, and 75 mg/kg for 14 days resulted in significant changes in hematological endpoints, most notably reductions in red blood cells, hematocrit and hemoglobin. SRI-011381 reduces neurodegeneratio in APP751Lon, Swetransgenic mice. |
| Synonyms | SRI-011381 hydrochloride [1629138-41-5(free base)] |
| Molecular Weight | 365.94 |
| Formula | C20H32ClN3O |
| Cas No. | 2070014-88-7 |
| Smiles | Cl.O=C(NC1CCCCC1)N(CC1CCNCC1)Cc1ccccc1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 12 mg/mL (32.79 mM), Sonication is recommended. H2O: 76.92 mg/mL (210 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.47 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||||||||||||
DMSO/H2O
H2O
| |||||||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.